Abstract:
This study aimed to evaluate the long-term clinical outcomes of drug-coated drug (DCB) angioplasty for long femoropopliteal lesions in older patients with chronic limb-threatening ischemia (CLTI). In this multi-center retrospective study, we enrolled 119 patients with CLTI due to Trans-Atlantic Inter-Society Consensus (TASCII) C/D femoropopliteal lesions who underwent DCB angioplasty. A total of 119 patients with 122 limbs (TASCII C = 67, 54.9%; TASCII D = 55, 45.1%) were enrolled. At 36-month follow-up, primary patency, assisted primary patency, secondary patency, and freedom from target lesion revascularization were 47.3%, 49.8%, 59.5%, and 62.7%, respectively, and there was a significant improvement over baseline in Rutherford class (P < .001) and ankle-brachial index measurements (P < .001). Complex target lesions (P = .017) and 1 stenosis-free outflow vessel (P = .001) were risk predictors of freedom from clinically driven target lesion revascularization. Complex target lesions (P = .044), diabetes (P = .007), and 1 stenosis-free outflow vessel (P = .003) were risk predictors of restenosis. At 2 months, the ulcer healing rate was 96.3% (26/27). At 36 months, the limb salvage and survival rates were 85.8% and 83.3%, respectively. DCB angioplasty were safe and effective for older patients with CLTI attributable to femoropopliteal TASCII C/D lesions.
摘要:
本研究旨在评估药物涂层药物(DCB)血管成形术治疗老年慢性威胁肢体缺血(CLTI)患者股pop骨长发病变的长期临床疗效。在这项多中心回顾性研究中,我们纳入了119例因跨大西洋社会共识(TASCII)C/D股pop病变而接受DCB血管成形术的CLTI患者.共纳入119例122肢患者(TASCIIC=67,54.9%;TASCIID=55,45.1%)。在36个月的随访中,初级通畅,辅助初级通畅,二级通畅,靶病变血运重建的自由度为47.3%,49.8%,59.5%,和62.7%,分别,卢瑟福级(P<.001)和踝肱指数测量值(P<.001)与基线相比有显著改善。复杂靶病变(P=.017)和1个无狭窄流出血管(P=.001)是临床驱动的靶病变血运重建的风险预测因子。复杂靶病变(P=.044),糖尿病(P=0.007),1个无狭窄流出血管(P=0.003)是再狭窄的风险预测因子。2个月时,溃疡愈合率为96.3%(26/27)。36个月时,保肢率和成活率分别为85.8%和83.3%,分别。DCB血管成形术是安全和有效的老年患者CLTI归因于股popTASCIIC/D病变。